Fund net buying at Appili Therapeutics (T:APLI)

The K2 Principal Fund L.P., a 10% Holder, acquired 178,800 Common Shares Class A Common Shares on a direct ownership basis at prices ranging from $1.281 to $1.368 between December 14th and 18th, 2020. This represents a $230,465 net investment into the company's shares and an account share holdings change of 3.1%.

Appili Therapeutics is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Appili Therapeutics Inc is a Canada-based pharmaceutical company. The Company is focused on the acquisition and development of treatments targeting infectious disease. The Company is focused on building and advancing adverse portfolio of anti-infective programs. The Company's anti-infective portfolio includes ATI-2307, ATI-1701, ATI-1503, ATI-1501 and Favipiravir. The ATI-2307 is a clinical-stage antifungal candidate in development for severe and difficult-to-treat invasive fungal infections. The ATI-1701 is a vaccine candidate for tularemia. The ATI-1503 is a drug discovery program aimed at generating a class of antibiotics with broad spectrum activity against gram-negative superbugs. The ATI-1501 employs its taste-masked, oral-suspension technology with metronidazole for the patients with difficulty swallowing.